All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What is the rationale for using BET inhibitors to treat myelofibrosis?
Featured
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak to Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What is the rationale for using bromodomain and extraterminal (BET) inhibitors to treat myelofibrosis?
What is the rationale for using BET inhibitors to treat myelofibrosis?
Harrison opens by discussing the unmet needs for patients with myelofibrosis who are unresponsive or intolerant to typical treatments such as ruxolitinib. The clinical applications of BET inhibitors are summarized, including the targeting of nuclear factor kappa B pathways, megakaryopoiesis, and erythropoiesis. Harrison concludes by highlighting the recent advancements in BET inhibitors for this indication and the latest updates published at the ASH Annual Meeting and Exposition.
Your opinion matters
9 votes - 1 day left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox